Medici List

Avenue Therapeutics is a Fortress-controlled specialty pharmaceutical company developing ATX-04 (clenbuterol) for lysosomal storage diseases (initially Pompe disease) and IV tramadol for postoperative pain, with no approved products and minimal internal resources.

Company Name (placeholder) reported a net loss of $17,298,000 in 2025 (compared with a net loss of $19,791,000 in 2024), total assets of $47,892,000 and cash of $5,200,000; the provided statements do not report revenue, customer count, or employee count.

Annexon is a clinical-stage biopharmaceutical company developing targeted immunotherapies that selectively inhibit the classical complement cascade (starting at C1q) to treat autoimmune, neurodegenerative, and ophthalmic diseases.

AIxCrypto Holdings, Inc. is a Nasdaq-listed technology infrastructure company building regulatory-aware real-world asset tokenization and Embodied AI deployment platforms to connect traditional capital markets with on-chain and AI-enabled commercial systems.

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-emitter radiopharmaceutical therapeutics and conditioning agents for oncology and cell/gene therapies with integrated isotope production and manufacturing plans.

A development-stage company with minimal product revenue ($124,157 in 2025) and substantial R&D and operating expenses, reporting a net loss of $14,771,012 in 2025, large intangible assets (~$19.2M) and significant convertible debt on the balance sheet.

Operates clinical treatment programs in the U.S.; fiscal 2025 revenue was $88,000 with a net loss of $13,958,000, driven by substantial R&D and G&A expenses and large noncash warrant/derivative-related items.

AEI Income & Growth Fund XXI Limited Partnership is a Minnesota limited partnership that acquires and holds single-tenant, net-leased commercial properties in the U.S., leases them to tenants, and periodically sells properties to realize gains and distribute proceeds to partners.

The Company (name not provided) — 2025 balance sheet shows total assets of $391,275, total liabilities of $465,990 and a shareholders' deficit of $74,715, with material deferred offering costs and a related‑party promissory note.

A Cayman Islands‑incorporated blank-check (SPAC) formed to complete a single business combination—targeting digital assets and blockchain—with no operating revenues or customers and IPO proceeds held in a trust to finance the acquisition.

Medical device company developing and commercializing catheter-based therapies for cardiac arrhythmias using Ultra-Low Temperature Ablation (ULTA) technology, initially focused on ventricular tachycardia (VT).

1606 Corp is a Nevada corporation focused on acquiring power infrastructure and developing and licensing AI chatbot solutions for the CBD industry and a public-company investor-IR vertical, while pursuing a Texas power facility acquisition to support data center/AI operations.